Editorial policy
MeinePeptide is an educational reference. This policy explains how we research, write, review, and correct our content so you can judge how much to trust it.
How we source information
Every peptide entry is built from peer-reviewed literature, clinical-trial registries, and the published guidance of regulatory bodies such as the FDA, EMA, BfArM, and Anvisa. Each page links the primary studies it draws on in its references section. We prioritise systematic reviews and human trials over preclinical or anecdotal reports.
How we grade evidence
We label the strength of evidence on every compound — from regulatory-approved through to preclinical-only or anecdotal — so the maturity of the research behind a claim is never ambiguous. Approved-drug terminology and clinical schema are applied only to compounds that hold regulatory approval, never to research-only compounds.
How we review and update
Content is reviewed on a recurring cycle and whenever the underlying evidence changes. Each entry shows its last-updated date and, where it applies, its last-reviewed date. We revise pages when new trials are published or regulatory guidance shifts.
Corrections
If you find an error or an out-of-date claim, contact us and we will review and correct it. Substantive corrections are logged with the date they were made.
What this is not
MeinePeptide does not provide medical advice, diagnosis, or treatment, and is not a substitute for a qualified clinician. Many of the compounds covered here are research chemicals that are not approved for human use. Always consult a licensed healthcare professional before acting on anything you read here.